Compounds > dimiracetam
Page last updated: 2024-12-06

dimiracetam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dimiracetam is a synthetic nootropic drug belonging to the racetam family, known for its potential cognitive enhancing properties. It was initially developed as a treatment for Alzheimer's disease, but its clinical applications remain under investigation. It is structurally similar to piracetam, but with modifications aimed at improving its bioavailability and enhancing its effects on memory and learning. The exact mechanism of action of dimiracetam is not fully understood, but it is believed to act primarily as a positive allosteric modulator of AMPA receptors, enhancing glutamate-mediated synaptic transmission. Research suggests that dimiracetam may improve cognitive function in healthy individuals, as well as in patients with cognitive impairments. However, further studies are required to fully understand its efficacy and safety profile. Dimiracetam is currently not approved for medical use in any country, and its long-term effects remain unknown. It is primarily studied for its potential to enhance cognitive function, improve memory, and potentially treat cognitive disorders. The ongoing research explores its pharmacokinetic properties, its efficacy in various cognitive domains, and its potential therapeutic applications.'

dimiracetam: structure given in first source; an antiamnestic agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65955
CHEMBL ID337612
SCHEMBL ID195256
MeSH IDM0225909

Synonyms (34)

Synonym
dihydro-1h-pyrrolo(1,2-a)imidazole-2,5(3h,6h)-dione
dimiracetam [inn]
1h-pyrrolo(1,2-a)imidazole-2,5(3h,6h)-dione, dihydro-
dimiracetam
(+-)-dihydro-1h-pyrrolo(1,2-a)imidazole-2,5(3h,6h)-dione
CHEMBL337612
nt-11624
3,6,7,7a-tetrahydro-1h-pyrrolo[1,2-a]imidazole-2,5-dione
126100-97-8
AKOS006272567
dihydro-1h-pyrrolo[1,2-a]imidazole-2,5(3h,6h)-dione
unii-4aw7f70mzo
4aw7f70mzo ,
(+/-)-dihydro-1h-pyrrolo(1,2-a)imidazole-2,5(3h,6h)-dione
SCHEMBL195256
tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione
XTXXOHPHLNROBN-UHFFFAOYSA-N
2,5-dioxohexahydro-1h-pyrrolo[1,2-a]imidazole
2.5-dioxohexahydro-1h-pyrrolo[1,2-a]imidazole
2,5-dioxohexahydro-1-h-pyrrolo[1,2-a]imidazole
AC-32019
CS-0026742
DB13018
Q3707748
mfcd00867777
nt 11624
tetrahydro-5h-pyrrolo[1,2-a]imidazole-2,5(3h)-dione
SB17242
W17118
AS-56333
BFA10097
hexahydro-1h-pyrrolo[1,2-a]imidazole-2,5-dione
DTXSID20869732
HY-106856

Research Excerpts

Overview

Dimiracetam appears to be a promising and safe treatment for neuropathic pain conditions. There are very limited therapeutic options.

ExcerptReferenceRelevance
"Dimiracetam appears to be a promising and safe treatment for neuropathic pain conditions for which there are very limited therapeutic options."( Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain.
Bonanno, G; Di Cesare Mannelli, L; Fariello, RG; Farina, C; Ghelardini, C; Milanese, M; Misiano, P; Pittaluga, A, 2014)		1.39

Dosage Studied

ExcerptRelevanceReference
"3 and 1 mg/kg ip for most compounds), the presence of a bell-shaped dose-response curve and, generally, a reduction of biological activity after po administration."( Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
Banfi, S; Biagetti, R; Cerri, A; Dorigotti, L; Farina, C; Magnani, M; Pfeiffer, U; Pinza, M; Pozzi, O; Riccaboni, MT, 1993)		0.29
" Chronic dimiracetam dosing in the MIA and ART- induced models completely reverted hyperalgesia back to the level of healthy controls."( Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain.
Bonanno, G; Di Cesare Mannelli, L; Fariello, RG; Farina, C; Ghelardini, C; Milanese, M; Misiano, P; Pittaluga, A, 2014)		1.09
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID191743Percent reversal of scopolamine-induced amnesia rat following 1.0 mg/kg i.p.1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
AID191746Percent reversal of scopolamine-induced amnesia rat at 10 mg/kg po1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
AID179848Tested for efficiency in responding in radial maze test in rat on the day after treatment at 1 mg/kg sc along with Scopolamine at 50 ug/kg sc1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
AID191741Percent reversal of scopolamine-induced amnesia rat at 0.3 mg/kg ip1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
AID191747Percent reversal of scopolamine-induced amnesia rat at 30 mg/kg po1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
AID179850Tested for efficiency in responding in radial maze test in rat on the day of treatment at 1 mg/kg sc along with Scopolamine at 50 ug/kg sc1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
AID179849Tested for efficiency in responding in radial maze test in rat on the day before treatment at 1 mg/kg sc along with Scopolamine at 50 ug/kg sc1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
AID191742Percent reversal of scopolamine-induced amnesia rat at 0.3 mg/kg po1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
AID191745Percent reversal of scopolamine-induced amnesia rat following 10 mg/kg i.p.1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
AID322674Antihyperalgesic activity in Sprague-Dawley rat assessed as lesioned paw pressure threshold at 100 ug/kg, icv after 45 mins2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain.
AID190635Tested for running time in radial maze test in rat on the day before treatment at 1 mg/kg sc along with Scopolamine at 50 ug/kg sc1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
AID191744Percent reversal of scopolamine-induced amnesia rat at 1.0 mg/kg po1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
AID322673Antihyperalgesic activity in Sprague-Dawley rat assessed as lesioned paw pressure threshold at 100 ug/kg, icv after 30 mins2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain.
AID190634Tested for running time in radial maze test in rat on the day after treatment at 1 mg/kg sc along with Scopolamine at 50 ug/kg sc1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
AID322675Antihyperalgesic activity in Sprague-Dawley rat assessed as lesioned paw pressure threshold at 100 ug/kg, icv after 60 mins2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain.
AID190637Tested for running time in radial maze test in rats on the day of treatment at 1 mg/kg sc along with Scopolamine at 50 ug/kg sc1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's1 (14.29)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.16 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		2.1110pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.1510nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
gabapentin
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.		2.0410gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
oxiracetam
oxiracetam: structure in first source		1.9810organonitrogen compound;
organooxygen compound
piracetam
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.		1.9810organonitrogen compound;
organooxygen compound
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		3.2960pyrrole;
secondary amine
n-methylaspartate
N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.		2.4110amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		2.4110glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.110taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
duloxetine hydrochloride
Duloxetine Hydrochloride: A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.. (S)-duloxetine hydrochloride : A duloxetine hydrochloride in which the duloxetine moiety has S configuration.		2.1510duloxetine hydrochlorideantidepressant
nefiracetam
[no description available]		2.0410organonitrogen compound;
organooxygen compound
d-aspartic acid
[no description available]		2.4110aspartic acid;
D-alpha-amino acid		mouse metabolite
sorafenib
[no description available]		7.1110(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
levetiracetam
Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.		2.0410pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic
pregabalin
Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.		7.1510gamma-amino acidanticonvulsant;
calcium channel blocker
scopolamine hydrobromide
[no description available]		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Amnesia-Memory Loss
[description not available]		01.9810
Amnesia
Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7)		01.9810
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.0140
Nerve Pain
[description not available]		03.2150
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		03.2150
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		07.4110
Osteoarthritis of Knee
[description not available]		02.110
Allodynia
[description not available]		02.5120
Osteoarthritis, Knee
Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)		02.110